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Background. Adherence to antiviral therapy is important for HIV-infected people living in low- and middle-income countries,
because of poor access to alternative regimens. Methods. We conducted a cross-sectional survey of adherence in Cambodian
patients enrolled in the ESTHER program and treated with WHO ﬁrst-line regimen for at least 6 months. The survey was based
on a self-report questionnaire, drug assay, MCV measurement, visual analog scale, and viral load HIV RNA. Results. Two hundred
ﬁfty-nine patients treated for a median of 16 months participated in the survey. At inclusion in the program, 158 patients (61%)
were ARV-na¨ ıve. The virological success rate was 71% overall and 81% in previously ARV-naive patients. Considered individually,
the measures suggested perfect adherence in 71% to 93% of patients. In multivariate analysis adjusted for sex and therapeutic
status before HAART initiation, only the biological markers were associated with virological eﬃcacy. Self-funded treatment before
entry to the program was highly predictive of virological failure. Conclusion. Adherence was excellent in these Cambodian patients.
Biological markers were predictive of virological eﬃcacy. MCV might thus serve as a simple alternative for assessing adherence and
predicting virological eﬃcacy among patients receiving AZT- or d4T-based regimens.
1.Introduction
Since highly active antiretroviral therapy (HAART) became
widely available in industrialized countries, mortality and
morbidity among patients living with HIV/AIDS have been
substantially reduced [1]. Recently, access to ARV has
improved in low- and middle-income countries. In late
2007, three million people in such countries were receiving
HAART [2]. Numerous initiatives have shown that countries
such as Brazil, Thailand, and Senegal can provide HAART
on a large scale by using produced generic drugs [3–
5], and that smaller programs can provide HAART in
local healthcare centres [6–10]. These cohort studies also
demonstrated the eﬃcacy of World Health Organization-
(WHO-)recommended ﬁrst-line HAART regimens, mainly
thanks to excellent adherence to treatment [10–12].
It is particularly important to assess adherence during
HAART programs, mainly owing to the limited availability
of alternative regimens [13]. Indeed, poor adherence can
lead to the emergence of drug resistance [14–16], notably
to ﬁrst-line nonnucleoside reverse transcriptase inhibitor
(NNRTI-)based regimens recommended by WHO. In coun-
tries with poor access to laboratory monitoring (CD4 cell
count and viral load), it has been suggested that treatment
monitoring could be based simply on physical examination
and adherence evaluation [17]. Educational and support
programs can improve adherence [18–20].
Adherence is diﬃcult to evaluate, however. Self-report
questionnaires have been widely used, for their low cost and
simplicity, in both industrialized and developing countries
[21, 22]. Visual analog scales have also recently been used
to assess adherence [23, 24]. However, the accuracy of these2 AIDS Research and Treatment
Table 1: Description of the tools used to assess adherence.
N (%)
HAART dose missed in the last four days∗
Yes 5( 2 )
No 252 (98)
Dose delayed by >2 hours in the last four days∗
Yes 22 (8.5)
No 235 (91.5)
HAART dose missed the previous weekend∗
Yes 17 (6.6)
No 240 (93.4)
Self-report questionnaire (combining the above
three items)∗
At least one missed HAART dose 34 (13.2)





Antiretroviral drug concentrations (in ng/mL)
<1000 for EFV or <3000 for NVP 18 (7)
≥1000 for EFV or ≥3000 for NVP 241 (93)
Macrocytosis (MCV > 100fL)∗∗
No 23 (9.1)
Yes 229 (90.9)
∗Available for 257 patients, ∗∗Available for 252 patients.
methods can be undermined by issues of recall bias and
social desirability [24]. Antiretroviral (ARV) drug assay [25–
27] and electronic monitoring [28, 29] are more objective
but may be too complex and costly for use in developing
countries. Macrocytosis, deﬁned as a mean corpuscular
volume (MCV) exceeding 100fL, is common during treat-
ment with AZT- and d4T-containing regimens and has been
proposedasanalternativeandlessexpensivewayofassessing
adherence [30].
We therefore conducted a cross-sectional survey of HIV-
infected patients receiving NNRTI-based regimens through
the ESTHER program in Phnom Penh (Cambodia) in order
toidentifysimplertoolsfortheidentiﬁcationofnonadherent
patients and for the prediction of virological failure.
2. Patientsand Methods
2.1. Patients. In February 2003, the Cambodian Ministry of
Health and the French ESTHER initiative implemented a
free treatment program for patients living with HIV/AIDS
at Calmette hospital, Phnom Penh. HAART was prescribed
according to WHO recommendations (WHO stages III and
IV, irrespective of the CD4 cell count, or asymptomatic
patients with CD4 cell counts ≤200/µL) both to ARV-na¨ ıve
patients and to patients having previously paid for ARV
themselves. In keeping with national guidelines, ﬁrst-line
therapy consisted of two nucleoside reverse transcriptase
inhibitors (NRTIs) plus one NNRTI. The HAART combi-
nation was (AZT or d4T)/3TC/efavirenz (EFV) initially, but
was then switched to (AZT or D4T)/3TC/nevirapine (NVP)
after July 2004, owing to EFV supply problems. Patients
were seen in the hospital every month after enrolment, for
a physical examination and to record clinical and therapeutic
information. On HAART initiation, the patients also entered
a therapeutic education program run by nurses. The patients
were seen monthly for three months, or more if the
educational objectives were not reached (median duration
4.6 months, IQR: 3–6). The adherence study was restricted
to patients who had been on HAART for at least six months,
to increase the odds that they had met their educational
objectives.
2.2. Adherence Assessment. Adherence was assessed in an
outpatient clinic. A self-report questionnaire focusing on
recent drug intake was administrated. The questionnaire
consisted of the following three items: (i) “did you miss any
HAART doses during the last four days?,” (ii) “Were you late
for any of your intakes by more than two hours during the
last four days?,” and (iii) “did you miss any HAART doses
last week-end?.” Because of the low educational level of many
patients, one-third of the questionnaires were administered
by nurses.
A visual analog scale similar to that developed for pain
evaluation was also used. The patients were asked to position
a cursor between “never” (score 1) and “always” (score 10)
in response to the question: “In general, would you say you
take your treatment...?.” Any answer diﬀerent from 10 was
considered to represent nonadherence.
EFV and NVP plasma concentrations were measured
by using high-performance liquid chromatography (HLPC).
Patients were asked to come to the clinic in the morning
without having taken their daily dose of NVP, and 12
hours after their last dose of EFV. Patients with EFV and
NVP concentrations below 1000ng/mL and 3000ng/mL,
respectively, were considered nonadherent.
As all the patients took AZT or D4T, those with an MCV
of ≤100fL were considered nonadherent.
A blood sample was collected to determine the CD4 cell
count (CyFlow, Partec, Germany) and HIV RNA viral load
(ANRS second-generation (G2) real-time RT-PCR) [31].
2.3. Statistical Methods. All patients who had at least one
adherence assessment were included in the analysis. Among
the 341 patients meeting the inclusion criteria (including
more than 6 months of HAART), 13 patients (3.8%) had
died, 14 (4.1%) had been lost to follow-up, 9 (2.6%) had
been directed to others centers, 12 were on an LPV/r-
containing regimen, 8 were on a triple NRTI combination,
and 25 could not be evaluated. A total of 259 patients were
ﬁnally included in the analysis.
The association between each measure of adherence and
virologicalfailure(deﬁnedas>400HIVRNAcopies/mL)was
tested for signiﬁcance by using the Chi-square test. A logistic
regression model was used to evaluate the contribution ofAIDS Research and Treatment 3
Table 2: Association between the four measures of adherence and virological failure in the overall population.
N Virological failure: N (%) OR [95% CI] P
Self-report questionnaire (all three items)∗
100% adherent 223 63 (28.2) 1
At least one missed HAART dose 34 11 (32.3) 1.21 [0.56–2.64] .62
Visual analog scale∗
10 184 54 (29.3) 1
9 62 18 (29.1) 0.98 [0.52–1.85] .70
<9 11 2 (18.2) 0.54 [0.11–2.55]
Antiretroviral drug concentrations (ng/mL)
≥1000 for EFV or ≥3000 for NVP 241 61 (25.3) 1
<1000 for EFV or <3000 for NVP 18 13 (72.2) 7.67 [2.63 –22.40] <.0001
Macrocytosis (MCV ≥100fL)∗∗
Yes 229 62 (27.1) 1
No 23 12 (52.1) 2.94 [1.23–7] .015
Self-report questionnaire plus macrocytosis
100% adherent 200 56 (28) 1
At least one mistake 50 18 (36) 1.44 [0.75–2.78] .27
Self-report questionnaire plus drug assays
100% adherent 209 54 (25.8) 1
At least one mistake 48 20 (41.7) 2.05 [1.07–3.93] .031
OR: odds ratio; CI: conﬁdence interval, ∗Available for 257 patients, ∗∗Available for 252 patients.
the diﬀerent measures of adherence to predict virological
failure. All statistical analyses were performed using Stata 8
software (Stata Corporation, College Station; Texas, USA);
all tests were two-sided and P values <.05 were considered
signiﬁcant.
3. Results
Among the 259 patients evaluated, 151 (58%) were male.
Median age was 35 years (interquartile range (IQR), 31–41).
At inclusion in the program, the median CD4 cell count
was 93/µL (IQR, 38–173); 158 patients (61%) were ARV-
na¨ ıve and 101 (39%) had already taken ARV before entry
to the program (dual NRTI therapy in 63 cases and a ﬁxed-
dose combination of D4T/3TC/NVP in 38 cases). At the time
of the evaluation, HAART consisted of AZT/3TC/NVP in
183 (71%) patients, AZT/3TC/EFV in 46 patients (18%),
d4T/3TC/NVP in 17 patients (6%), and d4T/3TC/EFV in
14 patients (5%). The median CD4 cell count increments
at 6 and 12 months were, respectively, 54/µL (IQR, 18–105)
and 92/µL (31–144). At the study visit, the median treatment
duration was 16.1 months (IQR, 14.3–17.7). Viral load was
below 400 HIV RNA copies/mL in 71.5% (n = 185) of the
patients overall, and in 81% (n = 128) of the 158 ARV-na¨ ıve
patients.
As shown in Table 1, the diﬀerent measurements showed
that most patients were adherent. In particular, 241 patients
(93%) had drug concentrations above the thresholds used to
deﬁne nonadherence. The visual analog scale gave the lowest
level of adherence (71%).
The association between virological failure and the
diﬀerent measures of adherence was ﬁrst investigated in all
the patients (Table 2), and then in the previously ARV-na¨ ıve
patients only (Table 3). Except for the visual analog scale, the
diﬀerent measures were associated with virological failure in
univariate analysis, and the association was stronger in ARV-
na¨ ıve patients. In an attempt to improve the identiﬁcation
of nonadherent patients, we tested various combinations
of the measures of adherence. A patient was considered
nonadherent if any single measure indicated they were
nonadherent. When added to the self-report questionnaire,
MCV and drug assay each strengthened the association with
the virological response.
After adjustment for sex and therapeutic status at entry
to the ESTHER program, logistic regression showed that
the results of the self-report questionnaire did not correlate





Resistance to NNRTI-based regimens emerges rapidly when
adherence is poor. In our study, adherence was considered
“perfect”inmorethan90%ofpatients,whateverthemethod
used to estimate it, and 81% of previously ARV-na¨ ıve




Several factors could explain this good adherence. First,
treatment was free of charge for all the patients, thanks to
the ﬁnancial stability of the program. Second, good drug4 AIDS Research and Treatment
Table 3: Association between the four measures of adherence and virological failure in the previously HAART-na¨ ıve population.
N Virological failure: N (%) OR [95% CI] P
Self-report questionnaire (all three items)∗
100% adherent 134 22 (16.4) 1
At least one missed HAART dose 22 8 (36.4) 2.91 [1.09–7.76] .034
Visual analog scale∗
10 110 20 (18.1) 1
9 39 8 (20.5) 1.16 [0.46–2.90] .78
<9 7 2 (28.6) 1.8 [0.32–9.95]
Antiretroviral drug concentrations (ng/mL)
≥1000 for EFV or ≥3000 for NVP 149 24 (16.1) 1
<1000 for EFV or <3000 for NVP 9 6 (66.7) 10.42 [2.43–44.54] .002
Macrocytosis (MCV ≥ 100fL)∗∗
Yes 141 23 (16.3) 1
No 14 7 (50) 5.13 [1.64–16.02] .007
Self-report questionnaire and macrocytosis
100% adherent 121 18 (14.9) 1
At least one mistake 32 12 (37.5) 3.43 [1.43–8.22] .006
Self-report questionnaire and drug assays
100% adherent 129 20 (15.5) 1
At least one mistake 27 10 (37) 3.20 [1.28–8] .015
OR: odds ratio; CI: conﬁdence interval, ∗Available for 156 patients, ∗∗Available for 155 patients.
Table 4: Multivariate logistic regression: factors associated with
virological failure (N = 250).
OR [95% CI] P
Sex
Female 1
Male 0.59 [0.32–1.09] .094
Previously treated patients
No 1
Yes 3.98 [2.15–7.36] <.0001
Self-report questionnaire
100% adherent 1
At least one mistake 0.88 [0.36–2.14] .77
Macrocytosis
Yes 1
No 3.09 [1.17–8.18] .023
Plasma drug concentrations
≥1000 for EFV or ≥3000 for NVP 1
<1000 for EFV or <3000 for NVP 10.46 [3.06–35.78] <.0001
OR: odds ratio; CI: conﬁdence interval.
procurement and distribution practices avoided drug supply
disruption. Both points have been shown to be a signiﬁcant
cause of drug resistance and ARV failure in Uganda [34].
Third, the patients received therapeutic education aimed at
improving adherence [19]. The patients had been following
this program for between three and six months before being
evaluated for virological outcome and simultaneously, for
adherence.
Inlow-tomiddle-incomecountries,whereaccesstoviral
load assays is limited, HAART eﬃcacy is monitored by using
clinical and immunological criteria that have relatively low
positive predictive value for virological failure [35, 36]. In
order to improve the prediction of virological eﬃcacy, we
evaluated diﬀerent measures of adherence, both individually
and in combination. The questionnaire assessing drug intake
during the previous four days (two items) and the previous
week-end (one item) showed a high level of adherence, as
reported elsewhere [21, 33]. Nevertheless, the association
with virological failure was weak and was only signiﬁcant
in previously ARV-na¨ ıve patients. Moreover, this association
disappeared in multivariate analysis. These results may be
explained partly by issues of social desirability and the loss
of anonymity when the patient needed help from a nurse to
answer the questionnaire [25].
We also evaluated MCV and plasma drug assay, as more
objectivemeasurementsofadherence[25,26].Wefoundthat
93% of patients had drug concentrations within the target
range, suggesting a high level of adherence. The favorable
pharmacokinetic properties of NNRTIs, which have long
half-lives and good oral absorption, ensure consistent drug
concentrations and could thus explain this result. Never-
theless, even if the association between virological success
and optimal therapeutic drug concentrations was strong in
univariate and multivariate analysis, drug assays are diﬃcult
to implement in Cambodia, especially in the province where
most of patients lived. Furthermore, although drug assay
is readily available in low- to middle-income countries, it
is unlikely that it would be cost-eﬀective for monitoring
HAART.AIDS Research and Treatment 5
The absence of macrocytosis was associated with viro-
logical failure, as all the patients were on AZT- or d4T-
based regimens. The association was strong in previously
ARV-na¨ ıve patients and persisted in multivariate analysis. In
Cambodia, as well as in many other low- to middle-income
countries, AZT and d4T are the most widely used NRTIs,
in keeping with WHO recommendations. MCV was deter-
mined during standard automated blood analyses, which are
widely available in many district hospitals in Cambodia. This
parameter might thus be used in combination with clinical
and immunological criteria to monitor HAART exposure
and eﬃcacy.
Forty percent of our patients had taken dual NRTI
therapy or a ﬁxed dose combination of D4T/3TC/NVP
before entry to the ESTHER program, and the eﬃcacy of
the study regimens was lower in these patients than in
previously ARV-na¨ ıve patients. Self-funded treatment in the
private sector was signiﬁcantly associated with subsequent
virological failure, even after adjustment for other factors
[37]. This was conﬁrmed by our logistic regression analysis.
These patients probably had NRTI and/or NNRTI resistance
mutations (data not shown), and subsequent HAART was
often ineﬀective despite good adherence.
Resistance to NNRTIs and NRTIs is the most important
issue in low- to middle-income countries, where access
to protease inhibitors is limited. WHO-approved ﬁrst-line
HAART must be maintained as long as possible, and the
identiﬁcation of patients at risk of resistance must be
a priority. Unfortunately, access to viral load assay and
genotypic resistance tests is currently limited. As self-report
questionnaires may lack accuracy and as drug monitoring
is diﬃcult to implement, MCV could be an interesting
alternative marker of adherence. Viral load assay could be
added if MCV results suggest poor adherence.
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